Who has used Miguda? Does Miguda have to be played for three years in a row to be effective?

Miguda (zoledronic acid injection), the indication is for the use of osteoporosis in postmenopausal women. Used for **paget'S disease (degenerative osteitis).

This product is a colorless, clear liquid. For osteoporosis in postmenopausal women. Used for **paget'S disease (degenerative osteitis).

For osteoporosis**, the recommended dose is a single intravenous infusion of 5 mg of Miguda once a year.

There is insufficient evidence to support the use of the drug for more than 3 years. For paget'For S disease, the recommended dose is a single intravenous infusion of 5 mg of Miguda. This product is instilled through an infusion tube at a constant rate. The instillation time should not be less than 15 minutes.

Patients must be properly hydrated before the administration of this product, especially those who are also receiving diuretics**. For women with osteoporosis, if dietary intake is inadequate, appropriate calcium and vitamin D supplementation is necessary.

Also, for paget'For patients with S disease, it is strongly recommended to ensure that vitamin D and sufficient calcium supplements are supplemented within 10 days after receiving this product**, and at least 500mg of elemental calcium and vitamin D are supplemented twice a day. There are currently no data on the safety and efficacy of re** (after 1 year).

Pharmacology and toxicology

Zoledronic acid is a nitrogen-containing bisphosphonic acid compound that acts mainly on human bones and inhibits bone resorption through the inhibition of osteoclasts. Bisphosphonic acid compounds have a high affinity for mineralized bone and can selectively act on bone. Zoledronic acid can be rapidly distributed in the bone after intravenous injection and preferentially aggregates in areas of high bone transformation like other bisphosphonic acid compounds.

The main molecular target of zoledronic acid is farnesylpyrophosphate synthase in osteoclasts, but other mechanisms of action are not ruled out. Long-term trials in estrogen-deficient animals have shown that zoledronic acid can inhibit bone cell reabsorption and increase bone mineral density in the range of doses administered to multiples of the human dose.

Studies have shown a dose-dependent increase in bone strength and other skeletal mechanical properties. When administered at doses equivalent to multiples of the human dose, zoledronic acid can significantly improve the skeletal mechanical properties of ovarian resected animals compared with non-ovarian animals (control group).

Tissue morphological analysis showed that the typical response of bone to anti-bone resorption drugs was dose-dependent inhibition of osteoclast activity and activation frequency of bone sorghum and Harvard system reconstruction sites. Sustained bone remodeling was observed in animal bone samples administered with clinically relevant doses of zoledronic acid**.

No calcification defects, abnormal osteoid accumulation, and braided osteogenesis were found in ** animals.

The above information reference: Encyclopedia-Miguda.

I started my IV mid-day infusion the morning before yesterday, and I was filled with one bottle of fluid, a second bottle of Miguda, and then another bottle of fluid. There was no response for four hours after the injection, and I was still walking around the hospital and then taking a shower to sleep. But from about 12 o'clock in the evening, the reaction began, first fever, body temperature continued to rise, the highest reached, accompanied by back pain.

The doctor gave 3 tablets of antipyretic medicine before and after the infusion, and he drank a lot of water himself, but it didn't work. Later, ice packs were applied, and two bottles of fluids were replenished with intravenous infusion, but the fever still did not subside. The next morning, I changed another antipyretic pill, and it didn't take long for the fever to subside after sweating.

Yesterday afternoon there was a slight fever, but it didn't exceed. This is my first time taking medication, and I heard from the doctor that the reaction to the second injection will not be so intense. I hope so.

You can use a section first, and if the effect is not good, you should find out what is causing pain all over the body.

The cause is not wind pain, poor blood circulation and too many crystals in the blood.

caused by symptomatic treatment.

I just finished hanging this needle the day before yesterday, I had a fever of 40 degrees, my whole body bone headache was not like my own, stomach pain, I couldn't eat for three days, I was dizzy, as if my body was not my own.

Yes, Miguda is a new** osteoporosis injection, and there is no need to use other osteoporotic drugs after intravenous administration once within a year. But the premise is liver and kidney function.

If you want to be good and the blood calcium should be normal, you can come to the outpatient clinic after the holiday, and then decide whether to take the drug or not.

**Men with osteoporosis in large women with postmenopausal epithetal provenance.

Prevention of low-trauma hips.

Recurrence of fractures after fractures, prophylaxis and ** glucocorticoids.

The study of osteoporosis caused by osteoporosis and deformable osteitis confirmed that compared with placebo or positive control drug, there is no significant difference in the total incidence of serious adverse events, and most of the adverse events are mild to moderate. The administration method of this product in the above studies is once a year.

Drug interactions.

There is currently no definitive zoledronic acid.

Studies of interactions with other drugs. Zoledronic acid is not systematically metabolized and in vitro tests have shown that it does not affect human cells.

The pigment P450 enzyme system (see [Pharmacokinetics.])

Zoledronic acid does not have a high plasma protein binding rate (approximately 43-55) and therefore does not compete with drugs with high plasma protein binding rates.

Zoledronic acid is excreted by the kidneys. Therefore, special attention should be paid when combined with drugs that obviously affect renal function.

The above content reference: Encyclopedia - Miguda.

Summary. Miguda** osteoporosis usually requires continuous injection for three years, but it also depends on the individual's physique, condition and age, so it is recommended to inject under the guidance of a doctor. It is mainly suitable for postmenopausal women who have osteoporosis or osteitis.

The effect is also more obvious. It can also be more effective in relieving patients' pain and improving their quality of life. Miguda** is more expensive, usually injected once a year, 5 mg intravenously at a time.

Patients can be properly hydrated prior to dosing, especially those receiving diuretics** at the same time, and should take adequate vitamin D at the same time as Miguda**. In life, we should eat more high-calcium foods, pay attention to moderate exercise, and try to drink less carbonated drinks.

Miguda** osteoporosis is often injected continuously for three years, but it also depends on the individual's physique, condition and age, so it is recommended to inject Xuzhenmin under the guidance of a doctor. It is mainly suitable for menopausal women who have osteopathy or osteitis. The effect is also more obvious.

It can also be more effective in relieving patients' pain and improving their quality of life. Miguda** is more expensive, usually injected once a year, 5 mg intravenously at a time. Patients can be properly hydrated prior to dosing, especially those receiving diuretics** at the same time, and should take adequate vitamin D at the same time as Miguda**.

In life, we should eat more high-calcium foods, pay attention to moderate exercise, and try to drink less carbonated drinks.

Hello. Hello.

Female, 58 years old, received an infusion of Miguda on 04/08/21, do I still need an infusion this year? When can I get an infusion?

Is it necessary to extend the infusion for 3 years?

Yes, an infusion in April this year will do.

It was said that it would be infused 1 month earlier, that is, on March 8, right?

Between these 3-5 months you can do it.

Don't have to be a month in advance? Is it okay until May? Will it affect the effect? Can I go to the hospital and prescribe Miguda by myself? Do I need to take any other medications?

Try to get a shot in April, go to the hospital to prescribe it, and the specific medicine needs to follow the doctor's instructions.

Good. You can also consult a doctor at the hospital for more professional help.

Summary. Through Baiyun for you to find out. At present, Miguda** is identified as follows:

1.Whether it is domestic or imported, the ingredients of the drug are the same, all zoledronic acid, the difference is that the purity of the imported is slightly higher than that of the domestic one, but there is not much difference in the use effect 2The imported zoledronic acid is the original drug, while the domestic drug is a generic drug, which causes the difference between the domestic drug and the imported drug by several times.

Patients can choose according to their own situation.

Through Baiyun for you to find out. At present, Miguda ** is identified as follows:1

Whether it is domestic or imported, the ingredients of the drug are the same, all of them are zoledronic acid, the difference is that the purity of the imported is slightly higher than that of the domestic one, but the use effect is not much different2The imported zoledronic acid is the original drug, while the domestic one is a generic drug, so the number of dispatches has caused the difference between the domestic drug and the imported drug to be several times. Patients can choose according to their own situation.

Extended information: zoledronic acid is the only bisphosphonate that is administered intravenously once a year through osmosis, and it is convenient to use once a year: the usage and dosage of this product:

1.For osteoporosis**, the recommended dose of Piqi is a single intravenous infusion of 5 mg of Miguda once a year. There is insufficient evidence to support the use of the drug for more than 3 years.

2.For paget'For S disease, the recommended dose is a single intravenous infusion of 5 mg of Miguda. This product is instilled through an infusion tube at a constant rate.

The instillation time should not be less than 15 minutes.

Switzerland; Miguda is produced by Novartis Pharmaceuticals in Switzerland; Novartis Corporation (NYSE: NVS) is a leader in the global pharmaceutical industry and ranked 168th in the Fortune Global 500 in 2007.

Novartis is focused on growth areas in healthcare and has a diverse portfolio of innovative medicines, preventive vaccines and diagnostics, and consumer healthcare products to best meet the needs of patients and society. Novartis is the only company that is a leader in all four of these areas. Miguda was developed for the treatment of osteoporosis and PAGET in postmenopausal women'Drugs for S disease (deformable osteitis).

Snova Pharmaceuticals **** company development.

In 1996, two century-old companies on the Rhine in Switzerland, Ciba-Geigy and Sandoz, announced a merger to form Novartis. Under the leadership of Dr. Vasella, Chairman and CEO, Novartis has continued to grow.

Novartis is focused on growth areas in healthcare and has a diverse portfolio of innovative medicines, preventive vaccines and diagnostics, and consumer healthcare products to best meet the needs of patients and society. Novartis is the only company that is a leader in all four of these areas.

In 2007, Novartis achieved net sales of $39.8 billion and net revenues of $12 billion. The Group invested approximately US$6.4 billion in R&D. Headquartered in Basel, Switzerland, Novartis employs 98,000 people worldwide and operates in more than 140 countries.

In 2007 alone, Novartis' medicines and vaccines were used to prevent diseases in 800 million people around the world.

Novartis is derived from the Latin novae artes, which means "new technology". The company's Chinese name, Novartis, is based on the commitment to China, that is, to strive to improve the health and quality of life of the Chinese people through continuous innovation of products and services.